About the choice of acceptability limits in external quality assessment schemes;Réflexion sur le choix des limites acceptables dans les programmes d'évaluation externe de la qualité

Annales de Biologie Clinique

Volumn 65, Issue 6, 2007, Pages 677-684

  Scherrer, F ^a   Boisson, R C ^b,c   Cartier, R ^c,d   Cohen, R ^c,e,f   Eynard, J C ^c   Poggi, B ^a,c   Grafmeyer, D ^a,c,f  

^a CROIX ROUSSE HOSPITAL   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c ProBioQual   (France)

^d HÔPITAL NEUROLOGIQUE   (France)

^e EDOUARD HERRIOT HOSPITAL   (France)

^f UNIVERSITÉ LYON 1   (France)

Author keywords

Acceptability limits; External quality assessment schemes; Quality control

Indexed keywords

C REACTIVE PROTEIN; ELECTROLYTE; ENZYME; PLASMA PROTEIN;

ARTICLE; BLOOD; BLOOD ANALYSIS; FRANCE; HEALTH CARE QUALITY; HUMAN; LABORATORY; OBSERVER VARIATION; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY; STANDARD;

BLOOD CHEMICAL ANALYSIS; BLOOD PROTEINS; C-REACTIVE PROTEIN; ELECTROLYTES; ENZYMES; FRANCE; HUMANS; LABORATORIES; OBSERVER VARIATION; QUALITY ASSURANCE, HEALTH CARE; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY;

EID: 37049015796     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: 10.1684/abc.2007.0159     Document Type: Article

References (15)

1. Norme ISO 15 189. Laboratoires d'analyse de biologie médicale - Exigences concernant la qualité et la compétence. ISO, octobre 2003.
2. Fraser CG, Petersen PH. Analytical performance characteristics should be judged against objective quality specifications. Clin Chem 1999 ; 45 : 321-3.
3. Document LAB GTA 006 (version 00). Paris : Cofrac, juillet 2005.
4. Vassault A, Grafmeyer D, De Graeve J, Cohen R, Beaudonnet A, Bienvenu J. Analyses de biologie médicale : spécifications et normes d'acceptabilités à l'usage des validations de techniques. Ann Biol Clin (Paris) 1999 ; 57 : 685-95.
5. http ://www.westgard.com/biodatabase1.htm.
6. Ricos C, Alvarez V, Cava F, et al. Current databases on biological variation : pros, cons and progress. Scand J Clin Lab Invest 1999 ; 59 : 491-500.
7. Fraser CG. Biological variation : from principles to practice. Washington : AACC Press, 2001.
8. http ://www.westgard.com/clia.htm.
9. Sciacovelli L, Zardo L, Secchiero S, Plebani M. Quality specifications in EQA schemes : from theory to practice. Clin Chim Acta 2004 ; 346 : 87-97.
10. Biosca C, Ricos C, Lauzurica R, Petersen PH. Biological variation at long-term renal post-transplantation. Clin Chim Acta 2006 ; 368 : 188-91.
11. Fraser CG. Test result variation and the quality of evidence-based clinical guidelines. Clin Chim Acta 2004 ; 346 : 19-24.
12. Luraschi P, Brambilla S, Pagani A, Infusion I, Franzini C. Updating biological variation databases and selecting reasonably correct published values. Scand J Clin Lab Invest 2000 ; 60 : 733-6.
13. Rifai N, Ridker PM. Population distribution of C-Reactive Protein in apparently healthy men and women in the United States : implication for clinical interpretation. Clin Chem 2003 ; 49 : 666-9.
14. Chenillot O, Henny J, Steinmetz I, Herbeth B, Wagner C, Siest G. High-sensitivity C-reactive protein : biological variations and reference limits. Clin Chem Lab Med 2000 ; 38 : 1003-11.
15. Bonvicini P, Metus P, Pavon MA, Massimo T. Requirements for reproducibility, trueness and error of measurement in internal quality control schemes. Clin Chem Lab Med 2003 ; 4 : 693-9.